Although future studies are required to determine whether this mechanism operates in patient’s tumours, our in vivo analysis showing weak base drug sensitization using the RACK1–NHE6 competing peptide suggests that the increased endosomal pH gradient occurs in the context of hypoxic solid tumours. The gene discussed is RACK1; the disease is neoplasm.